The below document provides information on the social characteristics promoted by the BlueBox Global Technology Fund, a sub-fund of BlueBox Funds ("BlueBox Global Technology Fund" or the “Sub-Fund” – LEI: 549300Q3ZDD326K9N105) and the methodologies that are used to assess, measure and monitor these characteristics in accordance with:

•  Article 10 of Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability‐related disclosures in the financial services sector ("SFDR") and  

• Chapter IV, Section 1 of Commission Delegated Regulation (EU) 2022/1288 of 6 April 2022 supplementing Regulation (EU) 2019/2088 of the European Parliament and of the Council with regard to regulatory technical standards specifying the details of the content and presentation of the information in relation to the principle of ‘do no significant harm’, specifying the content, methodologies and presentation of information in relation to sustainability indicators and adverse sustainability impacts, and the content and presentation of the information in relation to the promotion of environmental or social characteristics and sustainable investment objectives in pre-contractual documents, on websites and in periodic reports ("Level II RTS").

Defined terms used in this disclosure (unless defined herein) are as set out in the BlueBox Funds offering documents. Terms used in the summary have the same meaning as in the rest of this website disclosure.

This document provides information on the social characteristics promoted by the BlueBox Precision Medicine Fund, a sub-fund of BlueBox Funds ("BlueBox Precision Medicine Fund" or the “Sub-Fund” – LEI: 5299006NWWBBCR8O7682) and the methodologies that are used to assess, measure and monitor these characteristics in accordance with:

• Article 10 of Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability‐related disclosures in the financial services sector ("SFDR") and

• Chapter IV, Section 1 of Commission Delegated Regulation (EU) 2022/1288 of 6 April 2022 supplementing Regulation (EU) 2019/2088 of the European Parliament and of the Council with regard to regulatory technical standards specifying the details of the content and presentation of the information in relation to the principle of ‘do no significant harm’, specifying the content, methodologies and presentation of information in relation to sustainability indicators and adverse sustainability impacts, and the content and presentation of the information in relation to the promotion of environmental or social characteristics and sustainable investment objectives in pre-contractual documents, on websites and in periodic reports ("Level II RTS"). 

Defined terms used in this disclosure (unless defined herein) are as set out in the BlueBox Funds offering documents. Terms used in the summary have the same meaning as in the rest of this website disclosure.